|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.258 SEK | +0.16% |
|
-10.65% | -36.14% |
| 05-06 | IRLAB Q1 operating result swings to profit of SEK 10.7 mln | RE |
| 05-06 | Irlab reports growth in revenue and operating profit | FW |
| Capitalization | 107M 11.59M 9.84M 9.01M 8.5M 15.86M 1.09B 16M 41.65M 526M 43.46M 42.55M 1.81B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 107M 11.59M 9.84M 9.01M 8.5M 15.86M 1.09B 16M 41.65M 526M 43.46M 42.55M 1.81B | EV / Sales 2025 |
2.91x | EV / Sales 2026 * | 1.05x |
| Free-Float |
73.75% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: IRLAB Therapeutics AB
| 1 day | +0.16% | ||
| 1 week | -10.65% | ||
| Current month | -10.65% | ||
| 1 month | -19.36% | ||
| 3 months | -25.56% | ||
| 6 months | -47.25% | ||
| Current year | -36.14% |
| 1 week | 1.17 |  | 1.36 |
| 1 month | 1.17 | | 1.65 |
| Current year | 1.17 | | 2.14 |
| 1 year | 1.17 | | 7.88 |
| 3 years | 1.17 | | 20.2 |
| 5 years | 1.17 | | 81.8 |
| 10 years | 1.17 | | 110 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2024 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 31/12/2012 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 31/12/2015 |
| Chairman | 73 | 06/05/2020 | |
| Chairman | 68 | 19/02/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | -10.65% | -82.74% | -86.02% | 11.59M | |
| -2.72% | -1.54% | +29.12% | +117.57% | 846B | |
| -0.53% | -2.58% | +43.51% | +36.91% | 533B | |
| -0.57% | -2.44% | +9.18% | +37.65% | 356B | |
| -0.94% | -0.97% | +22.40% | +12.53% | 324B | |
| +0.23% | -1.24% | +30.31% | +12.89% | 282B | |
| +0.05% | -2.19% | +24.69% | +23.30% | 278B | |
| -0.82% | -0.70% | +46.61% | -5.53% | 275B | |
| -1.76% | +4.42% | -34.66% | -49.14% | 203B | |
| +0.79% | +0.57% | +24.76% | +41.69% | 179B | |
| Average | -0.61% | -1.67% | +11.32% | +14.18% | 327.54B | |
| Weighted average by Cap. | -1.05% | -1.17% | +25.64% | +43.56% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 56.3M 6.1M 5.19M 4.75M 4.48M 8.36M 576M 8.43M 21.95M 277M 22.9M 22.42M 956M | 102M 11.06M 9.4M 8.6M 8.12M 15.14M 1.04B 15.27M 39.76M 502M 41.49M 40.62M 1.73B |
| Net income | -110M -11.89M -10.11M -9.25M -8.73M -16.28M -1.12B -16.43M -42.76M -540M -44.62M -43.68M -1.86B | -36.7M -3.98M -3.38M -3.09M -2.92M -5.45M -376M -5.5M -14.31M -181M -14.93M -14.61M -623M |
| Net Debt | - | - |
Employees
31
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/26 | 1.258 kr | +0.16% | 70,876 |
| 07/05/26 | 1.256 kr | -0.79% | 188,948 |
| 06/05/26 | 1.266 kr | +5.50% | 672,322 |
| 05/05/26 | 1.200 kr | -14.77% | 2,030,446 |
Annual profits - Rate of surprise
- Stock Market
- Equities
- IRLAB A Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition